Susquehanna International Group, LLP Bio Atla, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$1.88 - $3.46 $37,036 - $68,162	19,700 New	19,700 $67,000
Q3 2023 Nov 14, 2023	BUY	$1.7 - $3.07 $83,300 - $150,430	49,000 New	49,000 $83,000
Q1 2023 May 16, 2023	SELL	$2.3 - $8.25 $15,639 - $56,100	-6,800 Reduced 23.37%	22,300 $59,000
Q4 2022 Feb 14, 2023	SELL	$6.29 - $11.01 $531,505 - $930,345	-84,500 Reduced 74.38%	29,100 $240,000
Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $333,984 - $1.35 Million	113,600 New	113,600 $875,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $250,098 - $1.07 Million	57,100 New	57,100 $286,000

17.4M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $42.8M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.